Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $33.17 Million Position in Pfizer Inc. (PFE)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Pfizer Inc. (NYSE:PFE) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 929,142 shares of the biopharmaceutical company’s stock after purchasing an additional 38,508 shares during the period. Pfizer comprises about 0.8% of Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s portfolio, making the stock its 28th largest position. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owned about 0.06% of Pfizer worth $33,170,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in PFE. HL Financial Services LLC boosted its position in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after purchasing an additional 35,744 shares during the period. Hartford Financial Management Inc. boosted its position in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 835 shares during the period. Cadence Bank NA boosted its position in Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 1,428 shares during the period. Majedie Asset Management Ltd boosted its position in shares of Pfizer by 7.9% in the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after acquiring an additional 24,531 shares during the period. Finally, Stanley Laman Group Ltd. boosted its position in shares of Pfizer by 373.7% in the second quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 90,160 shares during the period. Institutional investors own 69.87% of the company’s stock.

A number of equities analysts have recently commented on the stock. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reiterated a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Societe Generale set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Morgan Stanley set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, UBS Group set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $39.25.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

Pfizer Inc. (NYSE PFE) traded down $1.87 during trading hours on Monday, reaching $34.67. 40,290,000 shares of the company traded hands, compared to its average volume of 20,260,000. The company has a market capitalization of $206,660.00, a PE ratio of 9.85, a P/E/G ratio of 2.20 and a beta of 0.94. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the business posted $0.47 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Thursday, February 1st. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is 38.64%.

Pfizer declared that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

WARNING: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $33.17 Million Position in Pfizer Inc. (PFE)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/05/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-33-17-million-stake-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply